Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies

Publication date: Available online 13 June 2019Source: CellAuthor(s): Daniel G.W. Alanine, Doris Quinkert, Rasika Kumarasingha, Shahid Mehmood, Francesca R. Donnellan, Nana K. Minkah, Bernadeta Dadonaite, Ababacar Diouf, Francis Galaway, Sarah E. Silk, Abhishek Jamwal, Jennifer M. Marshall, Kazutoyo Miura, Lander Foquet, Sean C. Elias, Geneviève M. Labbé, Alexander D. Douglas, Jing Jin, Ruth O. Payne, Joseph J. IllingworthSummaryThe Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the leading target for next-generation vaccines against the disease-causing blood-stage of malaria. However, little is known about how human antibodies confer functional immunity against this antigen. We isolated a panel of human monoclonal antibodies (mAbs) against PfRH5 from peripheral blood B cells from vaccinees in the first clinical trial of a PfRH5-based vaccine. We identified a subset of mAbs with neutralizing activity that bind to three distinct sites and another subset of mAbs that are non-functional, or even antagonistic to neutralizing antibodies. We also identify the epitope of a novel group of non-neutralizing antibodies that significantly reduce the speed of red blood cell invasion by the merozoite, thereby potentiating the effect of all neutralizing PfRH5 antibodies as well as synergizing with antibodies targeting other malaria invasion proteins. Our results provide a roadmap for structure-guided vaccine development to maximize antibody efficacy ag...
Source: Cell - Category: Cytology Source Type: research

Related Links:

[allAfrica] "There is still a huge amount of effort in trying to develop malaria vaccines."
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Authors: LoVerde PT Abstract Schistosomiasis is a major cause of morbidity in the world; it is second only to malaria as a major infectious disease. Globally, it is estimated that the disease affects over 250 million people in 78 countries of the world and is responsible for some 280,000 deaths each year. The three major schistosomes infecting humans are Schistosoma mansoni, S. japonicum, and S. haematobium. This chapter covers a wide range of aspects of schistosomiasis, including basic biology of the parasites, epidemiology, immunopathology, treatment, control, vaccines, and genomics/proteomics. In this chapt...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Publication date: Available online 9 July 2019Source: The LancetAuthor(s): Lode Schuerman
Source: The Lancet - Category: General Medicine Source Type: research
Condition:   Malaria, Vivax Intervention:   Biological: ChAd63 PvDBP and MVA PvDBP Sponsor:   University of Oxford Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Advances in medical technology continue apace, with sophisticated new medical devices and therapies becoming available on an ongoing basis. However, medical technology often comes at a premium, and for low-resource regions sometimes even relatively b...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Critical Care Diagnostics Emergency Medicine ENT Exclusive Genetics Materials Pathology Public Health Source Type: blogs
Advice comes as measles outbreaks strike Europe Related items fromOnMedica Rapid rise in flu consultations putting strain on GPs Parental confidence in immunisation programme ‘very high’ Doctors can help overcome ‘vaccine hesitancy’ Repeated flu jabs reduce hospital admissions Africans in the UK most likely to acquire malaria
Source: OnMedica Latest News - Category: UK Health Source Type: news
During pregnancy, Plasmodium falciparum-infected erythrocytes (IE) accumulate in the intervillous spaces of the placenta by binding to chondroitin sulfate A (CSA) and elicit inflammatory responses that are associated with poor pregnancy outcomes. Primigravidae lack immunity to IE that sequester in the placenta and thus are susceptible to placental malaria (PM). Women become resistant to PM over successive pregnancies as antibodies to placental IE are acquired. Here, we assayed plasma collected at delivery from Malian and Tanzanian women of different parities for total antibody levels against recombinant VAR2CSA antigens (F...
Source: Infection and Immunity - Category: Infectious Diseases Authors: Tags: Microbial Immunity and Vaccines Source Type: research
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Perspectives Source Type: research
Condition:   Malaria Intervention:   Biological: PfSPZ Vaccine Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clinical Trials | Cytology | Malaria | Malaria Vaccine | Vaccines